Drugs in MeSH Category Protein Kinase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	ERLOTINIB HYDROCHLORIDE	erlotinib hydrochloride	TABLET;ORAL	208396-001	Nov 5, 2019		DISCN	No	No
Handa Therap	PHYRAGO	dasatinib	TABLET;ORAL	216099-005	Dec 5, 2023		RX	Yes	Yes
Shilpa	ERLOTINIB HYDROCHLORIDE	erlotinib hydrochloride	TABLET;ORAL	211960-002	Nov 5, 2019	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Protein Kinase Inhibitors

Last updated: April 23, 2026

How does the Protein Kinase Inhibitors market behave by segment?

The MeSH class Protein Kinase Inhibitors covers small-molecule inhibitors targeting kinases across oncology and inflammation pathways. Market dynamics are driven by (1) depth of clinical differentiation (overall survival, progression-free survival, intracranial efficacy, CNS penetration, resistance profiles), (2) dosing and safety (diarrhea, hepatotoxicity, myelosuppression, hypertension, QT effects), and (3) competitive sequencing (front-line vs later-line positioning, combination adoption, line-of-therapy migration).

Oncology dominates MeSH relevance. The largest commercial share concentrates in solid tumors and hematologic malignancies where kinase inhibition is standard-of-care. Growth also comes from:

• Selective inhibitors and next-generation EGFR/ALK/BRAF/RET/ROS1 programs that address resistance mutations.
• Combination regimens that pair kinase inhibitors with immunotherapy or targeted agents, especially where monotherapy responses are limited.
• Biomarker-driven use that improves response rates but compresses addressable patient counts into narrower molecular subgroups.

Non-oncology adoption exists but is smaller. Inflammation and fibrosis programs using kinase pathways (for example, JAK and related families) generate steady but typically lower-margin and more label-structured demand than high-intensity oncology launches.

Key commercial drivers

Driver	Market impact	Where it shows up most
Resistance-driven switching	Rapid uptake for next-gen inhibitors when resistance mutations become common in practice	EGFR, ALK, RET/ROS1 programs
Line-of-therapy migration	New entrants displace earlier-line treatment if they show efficacy and manageable tolerability	TKIs vs immune combinations, front-line trials
Safety and chronic dosing	Chronic tolerability determines staying power, dose intensity, and adherence	MET, EGFR, ALK, multi-kinase agents
CNS penetration	Intracranial activity changes sequencing and payer preference	EGFR/ALK with brain metastases
Biomarker restriction	Increases efficacy but narrows patient pool	Broad registries vs mutation-defined labels

What do payers and providers prioritize in kinase inhibitor procurement?

Kinase inhibitor formularies tend to be shaped by:

• Relative efficacy within biomarker strata (especially progression-free survival and intracranial outcomes).
• Safety profile aligned to comorbidity (cardiac risk, hepatic monitoring burden, myelosuppression).
• Dose scheduling and discontinuation rates in real-world settings.
• Therapeutic interchange rules across generics and biosimilars analogs are less relevant for most small molecules, but switching pressure increases at patent cliffs.

Procurement also reflects practical administration constraints. Oral daily dosing improves access but increases pressure for toxicity management protocols and lab monitoring infrastructure, which can drive formulary complexity and prior authorization.

How do patent cliffs and lifecycle strategies affect market timing?

Kinase inhibitors face accelerating lifecycle pressure due to:

• Fixed patent expiries for original compounds,
• Late-stage label expansions that can extend effective exclusivity,
• Patent “thickets” built around formulations, polymorphs, dosing regimens, and specific method-of-treatment claims.

Commercially, the consequence is a wave-like adoption cycle:

• Launch and early growth
• Plateau during label expansion
• Competitive attrition as follow-on patents sustain exclusivity or delay generic entry
• Rapid revenue decline around true compound-family expiries where thicket strength is weak

Where are the patent “hot zones” in kinase inhibitor families?

Across kinase inhibitor portfolios, patent protection commonly concentrates in four zones:

1. Core compound claims (composition-of-matter)
2. Crystal form/polymorph claims (solid-state variants)
3. Formulation and process claims (manufacturing improvements, stability)
4. Method-of-use claims (biomarker-defined treatment, dosage regimens, combination regimens)

For business planning, the key is whether follow-on filings block generic entry on the same active ingredient or whether they merely repackage the same compound without enforceable differentiation.

What is the MeSH definition and why it matters for landscape mapping?

The NLM MeSH descriptor Protein Kinase Inhibitors is used for biomedical indexing and literature retrieval. It does not represent a single patent family, but it provides a deterministic scope for assembling a dataset of kinase inhibitor drugs in the published corpus.

For patent mapping, MeSH scope acts as a selection filter over drugs and target classes, then patents are assigned at the active ingredient or family level by named compound coverage rather than by MeSH term alone.

Source basis: NLM MeSH entry “Protein Kinase Inhibitors.” [1]

---

What is the patent landscape structure for Protein Kinase Inhibitors?

A complete patent landscape requires case-by-case claim mapping to specific active ingredients. With MeSH scope alone, patents cannot be assigned reliably without compound-level linking. The landscape structure for kinase inhibitors is consistent, however, and can be used to model enforceability and generic risk across typical families.

Typical patent layers found in kinase inhibitor portfolios

Layer	Claim type	Commercial role	Why it matters to generic entry
Base compound	Composition-of-matter	Core exclusivity	Often defines earliest expiry target
Solid-state	Polymorph/crystal form	Delay in some jurisdictions	Can block “generic form” if claims are specific and validated
Formulation	Solid dosage, excipients, stability	Product-level differentiation	Can restrict certain manufacturing routes
Dosing and use	Method-of-treatment, regimen	Extends effective life	Often easier to design around than compound claims, but can still create barriers
Combination	Specific co-administration protocols	Label extension defense	Requires proving non-infringement for defined regimens
Patent term adjustments / extensions	Regulatory exclusivity interplay	Extends time in-market	Depends on jurisdiction and regulatory filings

---

How does resistance biology shape patent filing strategy?

Protein kinase inhibitors are frequently improved through:

• Mutation-selective variants (e.g., gatekeeper and solvent-front resistance coverage),
• Next-generation binding modes (different interaction geometry),
• Selectivity windows to reduce off-target toxicities that force dose reductions.

Patent strategy typically mirrors this:

• New compounds get new composition-of-matter families.
• Biomarker-defined methods-of-use are used to secure enforceable label-specific claims.
• Combination patents are drafted once clinical data stabilizes around synergy and safety tolerability.

Business implication: the value of a pipeline asset often correlates with how defensibly it addresses a measurable resistance mechanism and how tightly claims track the relevant biomarker subgroup.

---

What do market players do at patent expiry points?

Near expiry, three market behaviors dominate:

• Active ingredient switching within classes where the clinician selects a next-gen inhibitor that retains efficacy after resistance.
• Price erosion as generics and authorized alternatives enter.
• Contracting changes that reward formulary adherence, toxicity management outcomes, and patient persistence.

From a patent perspective, companies often seek to:

• Convert clinical differentiation into method-of-use claims that align to payer-relevant decision points.
• Expand to broader biomarker coverage where feasible.
• Use life-cycle patents on formulations and solid state to extend product exclusivity.

---

Where are there measurable enforcement patterns across kinase inhibitors?

Across kinase inhibitor enforcement, practical outcomes tend to depend less on the mere existence of many patents and more on:

• Claim scope overlap with generic design choices
• Whether the challenged patents are foundational (composition-of-matter) or incremental (formulation/regimen)
• Jurisdiction-specific patent linkage systems that accelerate or slow generic launch timing

Business implication: the “quality” of patents (likelihood of valid and infringed claims surviving) matters more than count.

---

What is the actionable investment lens for Protein Kinase Inhibitors?

A due-diligence checklist for investors and R&D planners should focus on whether the company can maintain enforceability through the next demand cycle:

Enforceability and value protection checks

• Compound-family status: expiry dates for core composition claims in target jurisdictions
• Solid-state and formulation coverage: whether generic manufacturers can avoid the specific forms claimed
• Method-of-treatment scope: whether regimen claims reflect real-world prescribing (not just trial conditions)
• Combination entanglement: whether claims tie to co-admin schedules used in practice
• Litigation history: outcomes that indicate judicial view of claim strength

---

Can the patent landscape be summarized without drug-by-drug mapping?

The MeSH category provides indexing scope but not an enforceable patent list. The enforceable landscape must be built on the active ingredient roster included in “Protein Kinase Inhibitors,” then merged with patent assignees, filing jurisdictions, and claim families.

Because MeSH alone cannot uniquely identify active ingredients or link to specific patent documents, a complete and accurate patent landscape cannot be produced from the category definition alone. The correct workflow is: MeSH term → drug name list → active ingredient families → jurisdictional patent dossiers → claim family analysis.

---

Key Takeaways

• Market demand for Protein Kinase Inhibitors is shaped by resistance-driven switching, line-of-therapy positioning, and tolerability in chronic use.
• Patent value in kinase inhibitors depends on whether protections are foundational (composition-of-matter) or enforceably differentiated (solid-state, formulation, biomarker-specific method-of-use).
• Lifecycle strategies commonly cluster around formulation/solid-state and method-of-treatment claims mapped to biomarker and regimen practice.
• MeSH scope is useful for literature mapping but does not itself define a patent landscape without compound-level linkage.

---

FAQs

1) What does the MeSH term “Protein Kinase Inhibitors” cover?

It is an NLM MeSH descriptor used to index literature about protein kinase inhibitors as a broad drug class, spanning multiple kinase targets and therapeutic indications. [1]

2) What drives market share changes among kinase inhibitors?

Resistance coverage, line-of-therapy outcomes, intracranial efficacy (where relevant), and tolerability that supports dose intensity and persistence.

3) What patent layers most often extend effective exclusivity in kinase inhibitors?

Solid-state (polymorph/crystal forms), formulation/process, and method-of-treatment or dosing/regimen claims aligned to biomarker-defined labels.

4) Why is a compound-family view critical for generic risk?

Generic entry timing hinges on whether challengers can design around non-foundational patents and whether composition-level claims are still active.

5) How should investors structure patent diligence for kinase inhibitor assets?

They should map enforceable claim families to jurisdictions, identify foundational vs lifecycle protections, and test claim scope against likely generic design choices.

---

References

[1] National Library of Medicine. (n.d.). Protein Kinase Inhibitors (MeSH). MeSH Database. https://meshb.nlm.nih.gov/ (MeSH descriptor “Protein Kinase Inhibitors”).